The promise of omics approaches for pediatric drug development
- Author
- Sigrid Verhelst (UGent) , Tess Goessens (UGent) , Roger Peró Gascón (UGent) , Marthe De Boevre (UGent) , Francis Impens (UGent) , Dieter Deforce (UGent) and Maarten Dhaenens (UGent)
- Organization
- Abstract
- Omics are large-scale studies that comprehensively try to acquire and analyze a complete set of biomolecules. Their comprehensive nature makes them ideally suited for generating hypotheses on health and disease. Here, we present some of the most commonly applied omics and classify them according to the target molecules and biological processes they study. Omics approaches were enabled by two recent technical revolutions, that is, the sequencing of nucleotides and the mass measurement of biomolecules by mass spectrometry. In essence, genomics creates an image of the genotype, but it is the environment (exposomics) and aging that decide on the activity of the genes, which is studied by epigenomics and transcriptomics. Only when the mRNA is translated into proteins (proteomics), however, does the phenotype arise, with all the metabolites as in- and output (metabolomics). In pediatrics, where age creates a unique phenotype, the development of unique treatments, and drugs cannot exclusively be directed by genomics and require input from all other omics studies.
- Keywords
- Exposomics, Genomics, Hypothesis generating, Machine learning, Metabolomics, Molecular biology, Pharmacogenomics, Proteomics, Transcriptomics
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 673.07 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01J3YPTR2BZQBYMQAW2GQHNNXP
- MLA
- Verhelst, Sigrid, et al. “The Promise of Omics Approaches for Pediatric Drug Development.” Essentials of Translational Pediatric Drug Development : From Past Needs to Future Oportunities, edited by Elke Gasthuys et al., Academic press, 2024, pp. 257–80, doi:10.1016/b978-0-323-88459-4.00011-0.
- APA
- Verhelst, S., Goessens, T., Peró Gascón, R., De Boevre, M., Impens, F., Deforce, D., & Dhaenens, M. (2024). The promise of omics approaches for pediatric drug development. In E. Gasthuys, K. Allegaert, L. Dossche, & M. Turner (Eds.), Essentials of translational pediatric drug development : from past needs to future oportunities (pp. 257–280). https://doi.org/10.1016/b978-0-323-88459-4.00011-0
- Chicago author-date
- Verhelst, Sigrid, Tess Goessens, Roger Peró Gascón, Marthe De Boevre, Francis Impens, Dieter Deforce, and Maarten Dhaenens. 2024. “The Promise of Omics Approaches for Pediatric Drug Development.” In Essentials of Translational Pediatric Drug Development : From Past Needs to Future Oportunities, edited by Elke Gasthuys, Karel Allegaert, Lien Dossche, and Mark Turner, 257–80. Academic press. https://doi.org/10.1016/b978-0-323-88459-4.00011-0.
- Chicago author-date (all authors)
- Verhelst, Sigrid, Tess Goessens, Roger Peró Gascón, Marthe De Boevre, Francis Impens, Dieter Deforce, and Maarten Dhaenens. 2024. “The Promise of Omics Approaches for Pediatric Drug Development.” In Essentials of Translational Pediatric Drug Development : From Past Needs to Future Oportunities, ed by. Elke Gasthuys, Karel Allegaert, Lien Dossche, and Mark Turner, 257–280. Academic press. doi:10.1016/b978-0-323-88459-4.00011-0.
- Vancouver
- 1.Verhelst S, Goessens T, Peró Gascón R, De Boevre M, Impens F, Deforce D, et al. The promise of omics approaches for pediatric drug development. In: Gasthuys E, Allegaert K, Dossche L, Turner M, editors. Essentials of translational pediatric drug development : from past needs to future oportunities. Academic press; 2024. p. 257–80.
- IEEE
- [1]S. Verhelst et al., “The promise of omics approaches for pediatric drug development,” in Essentials of translational pediatric drug development : from past needs to future oportunities, E. Gasthuys, K. Allegaert, L. Dossche, and M. Turner, Eds. Academic press, 2024, pp. 257–280.
@incollection{01J3YPTR2BZQBYMQAW2GQHNNXP,
abstract = {{Omics are large-scale studies that comprehensively try to acquire and analyze a complete set of biomolecules. Their comprehensive nature makes them ideally suited for generating hypotheses on health and disease. Here, we present some of the most commonly applied omics and classify them according to the target molecules and biological processes they study. Omics approaches were enabled by two recent technical revolutions, that is, the sequencing of nucleotides and the mass measurement of biomolecules by mass spectrometry. In essence, genomics creates an image of the genotype, but it is the environment (exposomics) and aging that decide on the activity of the genes, which is studied by epigenomics and transcriptomics. Only when the mRNA is translated into proteins (proteomics), however, does the phenotype arise, with all the metabolites as in- and output (metabolomics). In pediatrics, where age creates a unique phenotype, the development of unique treatments, and drugs cannot exclusively be directed by genomics and require input from all other omics studies.}},
author = {{Verhelst, Sigrid and Goessens, Tess and Peró Gascón, Roger and De Boevre, Marthe and Impens, Francis and Deforce, Dieter and Dhaenens, Maarten}},
booktitle = {{Essentials of translational pediatric drug development : from past needs to future oportunities}},
editor = {{Gasthuys, Elke and Allegaert, Karel and Dossche, Lien and Turner, Mark}},
isbn = {{9780323884594}},
keywords = {{Exposomics,Genomics,Hypothesis generating,Machine learning,Metabolomics,Molecular biology,Pharmacogenomics,Proteomics,Transcriptomics}},
language = {{eng}},
pages = {{257--280}},
publisher = {{Academic press}},
title = {{The promise of omics approaches for pediatric drug development}},
url = {{http://doi.org/10.1016/b978-0-323-88459-4.00011-0}},
year = {{2024}},
}
- Altmetric
- View in Altmetric